Skip to main content

Glenn Crocker, Pachiappan Manickham, Anne Pilaro, Simon Tavar, Mark Caccavo, Gregory Lucier


Glenn Crocker was named the first chief executive of BioCity Nottingham, UK. Crocker previously was head of the UK biotechnology practice for the firm of Ernst & Young. He holds a PhD in immunology from Oxford University.


Pachiappan Manickham will direct the new microarray core service facility at the Blanchette Rockefeller Neurosciences Institute at Johns Hopkins University Shady Grove Campus in Gaithersburg, Md.


Anne Pilaro has joined Gaithersburg, Md.-based Gene Logic as senior director for regulatory affairs for subsidiary TherImmune Research. Pilaro was expert toxicologist for cellular and gene therapies with the Office of Therapeutics Research of the Food and Drug Administration.


Simon Tavaré, professor of biology, mathematics, and preventative medicine at the University of Southern California, has joined the scientific advisory board of BioDiscovery of Marina Del Rey, Calif. He is also a professor-at-large at the Keck Graduate Institute for Applied Life Sciences in Claremont, Calif. He holds a PhD in probability and statistics from the University of Sheffield, UK.


Mark Caccavo joins the derivatives unit of the investment bank of CE Unterberg, Towbin of New York, which services a life sciences clientele. Caccavo previously was a vice president for Charles Schwab.


Gregory Lucier was named president and CEO of Carlsbad, Calif.-based Invitrogen, the company said last week. Lucier previously was president and CEO of General Electric’s Medical Systems Information Technologies unit. Lucier holds an MBA degree from Harvard University and a bachelor’s degree in industrial engineering from Pennsylvania State University.


The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.